ECOG/ACRIN-EA3132: Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing

This is a study to evaluate treatment after surgery for head and neck cancer. The purpose of this study is to compare two treatment approaches that are currently used after surgery for head and neck cancer.

Learn more about the ECOG/ACRIN- EA3132 trial or contact the Protocol Office at 484-628-8193.

NRG-HN001: Randomized phase II and phase III studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA)

This study is being done to see how people with this type of cancer respond to different types or levels of chemotherapy, based on a specific viral marker in their blood. This viral marker is called the Epstein Barr virus (EBV). A more individualized approach to treating this type of cancer might be found using this blood marker.

Learn more about the NRG-HN001 trial or contact the Protocol Office at 484-628-8193.

NRG-HN004: A Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin

The purpose of this study is to compare any good and bad effects of usual radiation plus the study treatment, MEDI4736 (durvalumab), to the usual therapy of radiation plus cetuximab in patients with head and neck cancer who cannot take the drug cisplatin.

Learn more about the NRG-HN004 trial or call the Protocol Office at 484-628-8193.

NRG-HN005: A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer.

The purpose of this study is to compare the usual treatment of a standard-dose radiation given over six weeks with cisplatin chemotherapy to a reduced-dose radiation given over either six weeks with cisplatin or five weeks with the immunotherapy drug, nivolumab.

Learn more about the NRG-HN005 trial or call the Protocol Office at 484-628-8193.